Ligand validation:4PH9

IBP: IBUPROFEN

IBP is a Ligand Of Interest in 4PH9 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4PH9_IBP_B_601	85%	56%	0.069	0.933	0.63	1.06	-	1	0	0	100%	1
4PH9_IBP_A_601	84%	52%	0.074	0.936	0.76	1.08	1	2	0	0	100%	1
8ET0_IBP_A_703	79%	60%	0.111	0.956	0.58	0.94	-	-	0	0	100%	1
4RS0_IBP_A_706	33%	57%	0.227	0.906	0.76	0.91	-	-	0	0	100%	1
4JTR_IBP_A_401	78%	16%	0.104	0.947	2.43	1.28	6	2	7	0	100%	1
2WD9_IBP_B_1570	67%	42%	0.161	0.969	0.91	1.31	1	2	0	0	100%	1
6OCI_IBP_A_601	58%	58%	0.178	0.957	0.7	0.92	-	-	5	0	100%	1
1EQG_IBP_B_1701	52%	59%	0.176	0.933	1.17	0.42	1	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.